Skip to main content
. 2024 Apr 22;15:1358114. doi: 10.3389/fimmu.2024.1358114

Table 3.

Association between ANA positivity and the incidence risk of RA in the propensity-score matched cohort*.

Variables Non-adjusted Adjusted I
OR (95%CI) p-value OR (95%CI) p-value
ANA titers
 Negative Reference Reference
 1:100 3.95 (3.02, 5.17) <0.0001 3.95 (3.01, 5.18) <0.0001
 1:320 16.69 (9.49, 29.37) <0.0001 16.63 (9.44, 29.30) <0.0001
 1:1,000 17.49 (9.62, 31.79) <0.0001 17.34 (9.53, 31.54) <0.0001
ANA patterns
 Negative Reference Reference
 Nuclear homogeneous 16.89 (11.53, 24.74) <0.0001 16.81 (11.46, 24.65) <0.0001
 Nuclear speckled 3.42 (2.51, 4.64) <0.0001 3.40 (2.49, 4.63) <0.0001
 Centromere 4.17 (0.69, 25.25) 0.1198 4.19 (0.69, 25.36) 0.1198
 Nucleolar 1.62 (0.82, 3.23) 0.1680 1.62 (0.81, 3.23) 0.1683
 Cytoplasmic speckled 3.09 (1.77, 5.39) <0.0001 3.09 (1.77, 5.40) <0.0001
 Other patterns 3.25 (1.07, 9.83) 0.0373 3.24 (1.07, 9.82) 0.0377

*The propensity-score matched cohort included 598 patients in the RA group and 598 patients in the non-RA group.

RA, rheumatoid arthritis; ANA, antinuclear antibody; OR, odds ratio; 95% CI, 95% confidence interval.

Adjusted I: Adjusted for age, sex.